Imatinib mesylate does not counteract ovarian tissue fibrosis in postnatal rat ovary

Babak Asadi-Azarbaijani; Saskia Braber; Majorie van Duursen; Kirsi Jahnukainen; Regiane Santos; Irma Oskam

doi:10.1016/j.repbio.2019.03.003

Imatinib mesylate does not counteract ovarian tissue fibrosis in postnatal rat ovary

Babak Asadi-Azarbaijani^*, Saskia Braber, Majorie van Duursen, Kirsi Jahnukainen, Regiane Santos, Irma Oskam

^*Corresponding author for this work

AIMMS

Research output: Contribution to Journal › Article › Academic › peer-review

46 Downloads (Pure)

Abstract

Chemotherapy may result in ovarian atrophy, a depletion of the primordial follicle pool, diminished ovarian weight, cortical and stromal fibrosis. Imatinib mesylate is an anticancer agent that inhibits competitively several receptor tyrosine kinases (RTKs). RTKs play important roles in cell metabolism, proliferation, and apoptosis. In clinic, imatinib mesylate is also known as an anti-fibrotic medicine. In the present study, the impact of imatinib on the ovarian tissue was investigated by assessing ovarian tissue fibrosis in postnatal rat administered with or without imatinib for three days. Fibrosis in the ovarian tissue was determined by histology (Picrosirius and Masson's trichrome staining) and the protein expression of vimentin and alpha-smooth muscle actin (α-SMA). Furthermore, mRNA expression of Forkhead box transcription factor O1 and O3 (FOXO1 and FOXO3), which are markers of cell proliferation was quantified. A short-term exposure to imatinib showed to increase tissue fibrosis in ovaries. This was observed by Masson's trichrome staining. Exposure to imatinib led also to a down-regulation of vimentin protein expression and up-regulation mRNA expression of FOXO3. This may indicate a role of FOXO3 in ovarian tissue fibrosis in postnatal rat ovaries.

Original language	English
Pages (from-to)	133-138
Number of pages	6
Journal	Reproductive Biology
Volume	19
Issue number	2
Early online date	10 May 2019
DOIs	https://doi.org/10.1016/j.repbio.2019.03.003
Publication status	Published - Jun 2019

Funding

This research was supported by grants from the Norwegian National Advisory Unit on Women’s Health, Oslo University Hospital, Norway and Faculty of Veterinary Medicine, IRAS, Utrecht University, Utrecht, the Netherlands .

Funders	Funder number
IRAS
Norwegian Institute of Public Health
Norwegian National Advisory Unit on Women's Health
Norwegian National Advisory Unit on Women’s Health
Oslo University Hospital
Universiteit Utrecht

Keywords

FOXO1
FOXO3
Imatinib
Ovary
Tissue fibrosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.repbio.2019.03.003

Imatinib mesylate does not counteract ovarian tissue fibrosis in postnatal rat ovaryFinal published version, 1.31 MBLicence: Article 25fa Dutch Copyright Act

Persistent URL (handle)

Persistent link

Cite this

@article{a1902d2cc4f147c1abfd6b2f267090ff,

title = "Imatinib mesylate does not counteract ovarian tissue fibrosis in postnatal rat ovary",

abstract = "Chemotherapy may result in ovarian atrophy, a depletion of the primordial follicle pool, diminished ovarian weight, cortical and stromal fibrosis. Imatinib mesylate is an anticancer agent that inhibits competitively several receptor tyrosine kinases (RTKs). RTKs play important roles in cell metabolism, proliferation, and apoptosis. In clinic, imatinib mesylate is also known as an anti-fibrotic medicine. In the present study, the impact of imatinib on the ovarian tissue was investigated by assessing ovarian tissue fibrosis in postnatal rat administered with or without imatinib for three days. Fibrosis in the ovarian tissue was determined by histology (Picrosirius and Masson's trichrome staining) and the protein expression of vimentin and alpha-smooth muscle actin (α-SMA). Furthermore, mRNA expression of Forkhead box transcription factor O1 and O3 (FOXO1 and FOXO3), which are markers of cell proliferation was quantified. A short-term exposure to imatinib showed to increase tissue fibrosis in ovaries. This was observed by Masson's trichrome staining. Exposure to imatinib led also to a down-regulation of vimentin protein expression and up-regulation mRNA expression of FOXO3. This may indicate a role of FOXO3 in ovarian tissue fibrosis in postnatal rat ovaries.",

keywords = "FOXO1, FOXO3, Imatinib, Ovary, Tissue fibrosis",

author = "Babak Asadi-Azarbaijani and Saskia Braber and {van Duursen}, Majorie and Kirsi Jahnukainen and Regiane Santos and Irma Oskam",

year = "2019",

month = jun,

doi = "10.1016/j.repbio.2019.03.003",

language = "English",

volume = "19",

pages = "133--138",

journal = "Reproductive Biology",

issn = "1642-431X",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Imatinib mesylate does not counteract ovarian tissue fibrosis in postnatal rat ovary

AU - Asadi-Azarbaijani, Babak

AU - Braber, Saskia

AU - van Duursen, Majorie

AU - Jahnukainen, Kirsi

AU - Santos, Regiane

AU - Oskam, Irma

PY - 2019/6

Y1 - 2019/6

N2 - Chemotherapy may result in ovarian atrophy, a depletion of the primordial follicle pool, diminished ovarian weight, cortical and stromal fibrosis. Imatinib mesylate is an anticancer agent that inhibits competitively several receptor tyrosine kinases (RTKs). RTKs play important roles in cell metabolism, proliferation, and apoptosis. In clinic, imatinib mesylate is also known as an anti-fibrotic medicine. In the present study, the impact of imatinib on the ovarian tissue was investigated by assessing ovarian tissue fibrosis in postnatal rat administered with or without imatinib for three days. Fibrosis in the ovarian tissue was determined by histology (Picrosirius and Masson's trichrome staining) and the protein expression of vimentin and alpha-smooth muscle actin (α-SMA). Furthermore, mRNA expression of Forkhead box transcription factor O1 and O3 (FOXO1 and FOXO3), which are markers of cell proliferation was quantified. A short-term exposure to imatinib showed to increase tissue fibrosis in ovaries. This was observed by Masson's trichrome staining. Exposure to imatinib led also to a down-regulation of vimentin protein expression and up-regulation mRNA expression of FOXO3. This may indicate a role of FOXO3 in ovarian tissue fibrosis in postnatal rat ovaries.

AB - Chemotherapy may result in ovarian atrophy, a depletion of the primordial follicle pool, diminished ovarian weight, cortical and stromal fibrosis. Imatinib mesylate is an anticancer agent that inhibits competitively several receptor tyrosine kinases (RTKs). RTKs play important roles in cell metabolism, proliferation, and apoptosis. In clinic, imatinib mesylate is also known as an anti-fibrotic medicine. In the present study, the impact of imatinib on the ovarian tissue was investigated by assessing ovarian tissue fibrosis in postnatal rat administered with or without imatinib for three days. Fibrosis in the ovarian tissue was determined by histology (Picrosirius and Masson's trichrome staining) and the protein expression of vimentin and alpha-smooth muscle actin (α-SMA). Furthermore, mRNA expression of Forkhead box transcription factor O1 and O3 (FOXO1 and FOXO3), which are markers of cell proliferation was quantified. A short-term exposure to imatinib showed to increase tissue fibrosis in ovaries. This was observed by Masson's trichrome staining. Exposure to imatinib led also to a down-regulation of vimentin protein expression and up-regulation mRNA expression of FOXO3. This may indicate a role of FOXO3 in ovarian tissue fibrosis in postnatal rat ovaries.

KW - FOXO1

KW - FOXO3

KW - Imatinib

KW - Ovary

KW - Tissue fibrosis

UR - http://www.scopus.com/inward/record.url?scp=85065232406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065232406&partnerID=8YFLogxK

U2 - 10.1016/j.repbio.2019.03.003

DO - 10.1016/j.repbio.2019.03.003

M3 - Article

C2 - 31080158

AN - SCOPUS:85065232406

SN - 1642-431X

VL - 19

SP - 133

EP - 138

JO - Reproductive Biology

JF - Reproductive Biology

IS - 2

ER -

Imatinib mesylate does not counteract ovarian tissue fibrosis in postnatal rat ovary

Abstract

Funding

Keywords

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this